Table 1 Demographics of patients who completed the ACT versus did not complete the ACT
N = 95 n (%) | Completed ACT (n = 28) | Did not complete ACT (n = 67) | Total | p-value |
|---|---|---|---|---|
Employed outside home? | Â | Â | Â | 0.11 |
   Yes | 8 (29%) | 32 (48%) | 40 (42%) |  |
   No | 20 (71%) | 35 (52%) | 55 (58%) |  |
Race/ethnicity | Â | Â | Â | Â |
   White | 15 (54%) | 34 (51%) | 49 (52%) | 0.18 |
   Black/African-American | 8 (28%) | 23 (34%) | 31 (33%) |  |
   Latino | 2 (7%) | 9 (13.5%) | 11 (11%) |  |
   Other | 3 (11%) | 1 (1.5%) | 4 (4%) |  |
Highest grade completed | Â | Â | Â | Â |
   Some high school or less | 6 (21%) | 12 (18%) | 18 (19%) | 0.21 |
   High school graduate/some college | 20 (72%) | 40 (60%) | 60 (60%) |  |
   Post graduate/college | 2 (7%) | 15 (22%) | 17 (22%) |  |
Household income | Â | Â | Â | Â |
   $15,000 or less | 11 (44%) | 24 (37%) | 35 (38%) | 0.46 |
   $15,000–$30,000 | 9 (36%) | 20 (30%) | 29 (32%) |  |
   More than $30,000 | 5 (20%) | 22 (33%) | 27 (30%) |  |
Using this type of medication in the past 12 months | Â | Â | Â | Â |
   Beta agonists | 26 (38%) | 62 (34%) | 88 (35%) | 0.60 |
   Inhaled corticosteroid | 14 (20%) | 27 (15%) | 41 (16%) |  |
   Long acting beta agonists (LABA) | 2 (3%) | 4 (2%) | 6 (2%) |  |
   ICS/LABA | 12 (17%) | 38 (21%) | 50 (20%) |  |
   Oral corticosteroid | 2 (3%) | 16 (9%) | 18 (7%) |  |
   Mast cell stabilizers | 9 (13%) | 22 (12%) | 31 (12%) |  |
   Ipratroprium | 4 (6%) | 10 (5%) | 14 (6%) |  |
   Theophylline | 0 | 4 (2%) | 4 (2%) |  |